Inspire Advisors’s Puma Biotechnology PBYI Stock Holding History

Inspire Advisors’s Portfolio PBYI Stock Details PBYI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-49	Closed	-$1K	–	536
2020 Q4	$1K	Buy	+49	New	+$496	﹤0.01%	753

Other funds holding PBYI

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

CCM

Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return

GPP

Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Inspire Advisors's PBYI Position: Q1 2021 in Review

Inspire Advisors sold out of Puma Biotechnology (PBYI) in Q1 2021, closing a stake of 49 shares — an estimated $1K sold.

Inspire Advisors first reported a position in PBYI in Q4 2020 and held it in 1 quarter. The position peaked at $1K in Q4 2020. 118 funds tracked by Wall St. Rank hold PBYI as of Q1 2021.

Inspire Advisors reported no remaining Puma Biotechnology position as of Q1 2021 after selling out during the quarter.
Inspire Advisors sold 49 Puma Biotechnology shares in Q1 2021, an estimated $1K.
Inspire Advisors first reported a position in Puma Biotechnology in Q4 2020 and held it in 1 quarter.
Inspire Advisors's Puma Biotechnology position peaked at $1K in Q4 2020.
118 funds tracked by Wall St. Rank held Puma Biotechnology as of Q1 2021.

Based on Inspire Advisors's 13F filing for Q1 2021, filed 30 Apr 2021.